Emergent Health Corp (EMGE) Stock

About Emergent Health Corp

Emergent Health Corp. focuses on the creation and distribution of advanced regenerative medicine, alongside a variety of nutraceuticals and plant-derived nutritional supplements. The company's product portfolio features Vita-Stim, a potent nutrient formulated to strengthen the immune system, promote stem cell vitality, and support general well-being. Another key offering is Neuvitale, which not only assists in nourishing stem cells but also serves as a methyl donor to safeguard DNA integrity. For appetite regulation, they provide Hungarest, a dietary aid designed to manage hunger signals originating from both the brain and stomach. Additionally, EmergentO2 is available as a water oxygenator, aiming to elevate oxygen levels within the bloodstream. The firm also develops and markets several solutions for diminishing facial wrinkles. These products are distributed through a wide network of health food stores, pharmacies, and diverse other retail channels, reaching consumers throughout the United States and globally. Based in King of Prussia, Pennsylvania, Emergent Health Corp. transitioned to private ownership as of August 26, 2014.

Emergent Health Corp (EMGE) stock trades at $0.00 with a market capitalization of $4193. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of -0.02, price-to-sales of 0.36. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Emergent Health Corp generates a return on equity (ROE) of -164.17%, return on capital employed of 59.85%, an operating margin of -289.95%, a net profit margin of -241.51%.

Official website: www.gemelles.com